Compare Merck & Co., Inc. (MRK) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Redwire Corporation — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Redwire Corporation trades at $10.73 (market cap $2.81B). The key difference: Merck & Co., Inc. is far larger — about 130.3× Redwire Corporation's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.
| MRK | RDW | |
|---|---|---|
Market Cap | $366.28B | $2.81B |
Sector | Health | Technology |
52-Week High | $156.43 | $25.90 |
52-Week Low | $77.60 | $5.06 |
Enterprise Value | $413.04B | $2.34B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Redwire Corporation (RDW) trades at $11.23, up 6.65% today, with a bullish technical signal and strong analyst support. The stock shows improving revenue trends with 2026 projections reaching $426 million, though profitability remains challenged with negative margins. Recent news highlights strategic investments in phased-array technology and record backlog growth, while institutional interest is strong with BlackRock's $196.5 million position.
The outlook remains cautiously optimistic given 80% analyst buy ratings and a $12.17 price target, but significant risks persist including continued cash burn, execution challenges, and premium valuation. Investors face the tension between promising space/defense growth opportunities and the company's ongoing inability to achieve profitability despite revenue expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
